361 related articles for article (PubMed ID: 33435150)
1. Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future.
Minciacchi VR; Kumar R; Krause DS
Cells; 2021 Jan; 10(1):. PubMed ID: 33435150
[TBL] [Abstract][Full Text] [Related]
2. The legacy of the Philadelphia chromosome.
Koretzky GA
J Clin Invest; 2007 Aug; 117(8):2030-2. PubMed ID: 17671635
[TBL] [Abstract][Full Text] [Related]
3. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.
Osman AEG; Deininger MW
Blood Rev; 2021 Sep; 49():100825. PubMed ID: 33773846
[TBL] [Abstract][Full Text] [Related]
4. The prognostic importance of BCR-ABL transcripts in Chronic Myeloid Leukemia: A systematic review and meta-analysis.
Ghalesardi OK; Khosravi A; Azizi E; Ahmadi SE; Hajifathali A; Bonakchi H; Shahidi M
Leuk Res; 2021 Feb; 101():106512. PubMed ID: 33524640
[TBL] [Abstract][Full Text] [Related]
5. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
Yung Y; Lee E; Chu HT; Yip PK; Gill H
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440869
[TBL] [Abstract][Full Text] [Related]
6. Future Approaches for Treating Chronic Myeloid Leukemia: CRISPR Therapy.
Vuelta E; García-Tuñón I; Hernández-Carabias P; Méndez L; Sánchez-Martín M
Biology (Basel); 2021 Feb; 10(2):. PubMed ID: 33557401
[TBL] [Abstract][Full Text] [Related]
7. Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge.
Iurlo A; Cattaneo D; Bucelli C; Breccia M
J Clin Med; 2021 Feb; 10(3):. PubMed ID: 33535564
[TBL] [Abstract][Full Text] [Related]
8. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.
Rowley JD
Nature; 1973 Jun; 243(5405):290-3. PubMed ID: 4126434
[No Abstract] [Full Text] [Related]
9. Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review.
Sampaio MM; Santos MLC; Marques HS; Gonçalves VLS; Araújo GRL; Lopes LW; Apolonio JS; Silva CS; Santos LKS; Cuzzuol BR; Guimarães QES; Santos MN; de Brito BB; da Silva FAF; Oliveira MV; Souza CL; de Melo FF
World J Clin Oncol; 2021 Feb; 12(2):69-94. PubMed ID: 33680875
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukaemia.
Cortes J; Pavlovsky C; Saußele S
Lancet; 2021 Nov; 398(10314):1914-1926. PubMed ID: 34425075
[TBL] [Abstract][Full Text] [Related]
11. Third-line therapy for chronic myeloid leukemia: current status and future directions.
Cortes J; Lang F
J Hematol Oncol; 2021 Mar; 14(1):44. PubMed ID: 33736651
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in understanding chronic myeloid leukemia: where do we stand?
Kumar R; Krause DS
Fac Rev; 2021; 10():35. PubMed ID: 33977288
[TBL] [Abstract][Full Text] [Related]
13. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
Singh P; Kumar V; Gupta SK; Kumari G; Verma M
Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624
[TBL] [Abstract][Full Text] [Related]
14. Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
Stuckey R; López-Rodríguez JF; Sánchez-Sosa S; Segura-Díaz A; Sánchez-Farías N; Bilbao-Sieyro C; Gómez-Casares MT
World J Clin Oncol; 2020 Dec; 11(12):996-1007. PubMed ID: 33437662
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Guilhot F; Rigal-Huguet F; Guilhot J; Guerci-Bresler AP; Maloisel F; Rea D; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Jourdan E; Berger M; Fouillard L; Alexis M; Legros L; Rousselot P; Delmer A; Lenain P; Escoffre Barbe M; Gyan E; Bulabois CE; Dubruille V; Joly B; Pollet B; Cony-Makhoul P; Johnson-Ansah H; Mercier M; Caillot D; Charbonnier A; Kiladjian JJ; Chapiro J; Penot A; Dorvaux V; Vaida I; Santagostino A; Roy L; Zerazhi H; Deconinck E; Maisonneuve H; Plantier I; Lebon D; Arkam Y; Cambier N; Ghomari K; Miclea JM; Glaisner S; Cayuela JM; Chomel JC; Muller M; Lhermitte L; Delord M; Preudhomme C; Etienne G; Mahon FX; Nicolini FE;
Leukemia; 2021 Aug; 35(8):2332-2345. PubMed ID: 33483613
[TBL] [Abstract][Full Text] [Related]
16. Current status and novel strategy of CML.
Morita K; Sasaki K
Int J Hematol; 2021 May; 113(5):624-631. PubMed ID: 33782818
[TBL] [Abstract][Full Text] [Related]
17. MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial.
Seguro FS; Maciel FVR; Santos FM; Abdo ANR; Pereira TDM; Nardinelli L; Rocha V; Bendit I
Leuk Res; 2021 Feb; 101():106516. PubMed ID: 33517185
[TBL] [Abstract][Full Text] [Related]
18. Pre-transplant use of tyrosine kinase inhibitors and transplant associated thrombotic microangiopathy - a single centre analysis of incidence, risk factors and outcomes.
Punatar S; Kalantri SA; Chichra A; Agrawal AK; Nayak L; Bonda A; Gokarn A; Bagal B; Mathew L; Kannan S; Khattry N
Bone Marrow Transplant; 2021 Jul; 56(7):1558-1562. PubMed ID: 33514924
[TBL] [Abstract][Full Text] [Related]
19. Eradicating residual chronic myeloid leukaemia: basic research lost in translation.
Zhao H; Deininger M
Lancet Haematol; 2021 Feb; 8(2):e101-e104. PubMed ID: 33513367
[No Abstract] [Full Text] [Related]
20. Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells.
Riether C; Radpour R; Kallen NM; Bürgin DT; Bachmann C; Schürch CM; Lüthi U; Arambasic M; Hoppe S; Albers CE; Baerlocher GM; Ochsenbein AF
Cell Rep; 2021 Jan; 34(4):108663. PubMed ID: 33503440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
